ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc.
Company typeSubsidiary
Nasdaq: ISTA
IndustryPharmaceuticals
Founded1992; 32 years ago (1992)
HeadquartersIrvine, California
Key people
  • Vicente Anido Jr., Ph.D. (president, CEO)
  • Glenn E. Davis (vice president, Chief Compliance Officer)
  • Marvin J. Garrett (vice president, Regulatory Affairs, Quality & Compliance)
  • Kathleen McGinley (Vice President, Human Resources & Corporate Services)
ProductsBromday, Bepreve, Xibrom, Istalol, Vitrase
Websitewww.istavision.com

ISTA Pharmaceuticals, Inc., was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012.[2] Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million.[3] In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[4]

  1. ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved October 28, 2009.
  2. ^ Lattman, Peter (26 March 2012). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved January 29, 2019.
  3. ^ Lattman, Peter (2012-03-26). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved 2019-10-21.
  4. ^ Scott, Mark (4 September 2012). "Valeant Sticks to Torrid Pace of Deal-Making". DealBook. Retrieved January 29, 2019.